Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for KRAS G12C-mutant colorectal cancer, drawn from the whole corpus: 25 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Responses last months, not years; acquired RAS and MAPK alterations drive resistance.
Nothing recorded yet.
Background: Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
G12D, the commonest colorectal KRAS allele, has no approved drug.
Nothing recorded yet.
Background: RAS / RAF / MEK / ERK (MAPK). Also on OnCo: Targets · KRAS roadmap.
First-line use of the combinations awaits CodeBreaK 301 and KRYSTAL-10.
Anti-EGFR skin and magnesium toxicity limits the combinations for some patients.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 16 changes by month →When this page itself was last checked or edited.
KRAS G12C colorectal cancer with panitumumab (CodeBreaK 300)
KRAS G12C colorectal cancer with panitumumab
A milestone in how this cancer is treated.
KRAS G12C colorectal cancer with cetuximab (accelerated)
KRAS G12C colorectal cancer with cetuximab